Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004388 · ClinicalTrials.gov registry record · Phase 3
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
A Phase 3 study of Migraine and Headache, sponsored by Click Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT06004388: Completed Phase 3 study of Migraine and Headache, sponsored by Click Therapeutics.
NCT06004388 is a Phase 3 study of Migraine and Headache that has completed, run by Click Therapeutics. The registered enrollment target is 110 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06004388, a Phase 3 study of Migraine and Headache, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
Primary Outcome
Change from baseline in the number of Monthly Migraine Days (MMDs) at Week 12
Conditions Studied
Interventions
- DEVICE Click Digital Therapeutic
Study Locations (1)
New York
- Click Therapeutics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2024-06-05 |
| Phase | Phase 3 |
What the finished NCT06004388 record still lists
NCT06004388 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (69% lower).
The record links to 4 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Click Digital Therapeutic is the first listed.
NCT06004388 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06004388 about?
NCT06004388 is a clinical study titled "Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)". Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
What is the current status of trial NCT06004388?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2023-07-21. Estimated completion is 2024-06-05.
What conditions does trial NCT06004388 study?
This clinical trial studies the following conditions: Migraine, Headache, Episodic Migraine, Headache, Migraine.
What interventions are being tested in trial NCT06004388?
The interventions under investigation include: Click Digital Therapeutic (DEVICE).
Who is sponsoring clinical trial NCT06004388?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004388 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06004388's enrollment target sits among peer trials
110 56th of 102 higher than 47 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI